Femtomole immunodetection of synthetic and endogenous amyloid-β oligomers and its application to Alzheimer’s disease drug candidate screening

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Molecular Neuroscience

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1385/JMN:20:3:305PMID 14501013
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics

  2009cited by this paper
• Per-6-substituted beta-cyclodextrin libraries inhibit formation of beta-amyloid-peptide (A beta)-derived, soluble oligomers.

  2002influential reference
• Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

  2002cited by this paper
• The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease.

  2002cited by this paper
• The Relationship between Aβ and Memory in the Tg2576 Mouse Model of Alzheimer's Disease

  2002cited by this paper
• Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

  2002cited by this paper
• Secretase as a target for Alzheimer's disease.

  2002cited by this paper
• Soluble oligomers of beta amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus.

  2002cited by this paper
• Per-6-substituted β-cyclodextrin libraries inhibit formation of β-amyloid-peptide (Aβ)-derived, soluble oligomers

  2002influential reference
• Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum?

  2001cited by this paper
• Vaccination with soluble Aβ oligomers generates toxicity‐neutralizing antibodies

  2001cited by this paper
• Oligomerization of β-amyloid of the Alzheimer’s and the Dutch-cerebral-haemorrhage types

  2000cited by this paper
• High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation

  2000influential reference
• Oligomerization of beta-amyloid of the Alzheimer's and the Dutch-cerebral-haemorrhage types.

  2000cited by this paper
• Self-assembly of beta-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates.

  2000cited by this paper
• Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

  1999cited by this paper
• Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain*

  1999cited by this paper
• Quantification of sub-femtomole amounts of Alzheimer amyloid β peptides

  1999cited by this paper
• Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease

  1999cited by this paper
• Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons

  1999cited by this paper
• Assembly of Aβ Amyloid Protofibrils: An in Vitro Model for a Possible Early Event in Alzheimer's Disease†

  1999cited by this paper
• Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models.

  1999cited by this paper
• An Ultrastructural Study of Amyloid Intermediates in Aβ1–42 Fibrillogenesis

  1999cited by this paper
• Quantification of sub-femtomole amounts of Alzheimer amyloid beta peptides.

  1999cited by this paper
• Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

  1998cited by this paper
• Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red.

  1998cited by this paper
• Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

  1998cited by this paper
• Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

  1997cited by this paper
• Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins.

  1997cited by this paper
• Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate.

  1997cited by this paper
• Assessment of Amyloid β Protein in Cerebrospinal Fluid as an Aid in the Diagnosis of Alzheimer's Disease

  1996cited by this paper
• Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease.

  1996cited by this paper
• Spatial learning deficit in mice expressing human 751-amino acid beta-amyloid precursor protein.

  1996cited by this paper
• Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

  1994cited by this paper

• Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases

  2025cites this paper
• Nanomaterials in targeting amyloid-β oligomers: current advances and future directions for Alzheimer's disease diagnosis and therapy

  2025cites this paper
• Critical thinking of Alzheimer’s transgenic mouse model: current research and future perspective

  2023cites this paper
• An Essential Role for Alzheimer’s-Linked Amyloid Beta Oligomers in Neurodevelopment: Transient Expression of Multiple Proteoforms during Retina Histogenesis

  2022cites this paper
• The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer’s Disease

  2022cites this paper
• Distinct types of amyloid‐β oligomers displaying diverse neurotoxicity mechanisms in Alzheimer's disease

  2021cites this paper
• Amyloid β oligomer selective antibodies for Alzheimer’s therapeutics and diagnostics

  2021cites this paper
• The Toxicity and Polymorphism of β-Amyloid Oligomers

  2020cites this paper
• TNFAIP1 Is Upregulated in APP/PS1 Mice and Promotes Apoptosis in SH-SY5Y Cells by Binding to RhoB

  2020cites this paper
• Targeting the neurotoxic species in Alzheimer’s disease: inhibitors of A (cid:1) oligomerization

  2020cites this paper
• Cyclodextrin Inclusion of Medicinal Compounds for Enhancement of their Physicochemical and Biopharmaceutical Properties.

  2019cites this paper
• An acute functional screen identifies an effective antibody targeting amyloid-β oligomers based on calcium imaging

  2018cites this paper
• The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

  2018cites this paper
• Hippocampal Neurodegenerative Pathology in Post-stroke Dementia Compared to Other Dementias and Aging Controls

  2017cites this paper
• Isoflurane anesthesia promotes cognitive impairment by inducing expression of β-amyloid protein-related factors in the hippocampus of aged rats

  2017cites this paper
• Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers

  2017cites this paper
• Alzheimer's disease as oligomeropathy

  2017influential citation
• Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer’s disease

  2017cites this paper
• Improved Neuroprotection Provided by Drug Combination in Neurons Exposed to Cell-Derived Soluble Amyloid-β Peptide

  2016cites this paper
• Amyloid β oligomers in Alzheimer’s disease pathogenesis, treatment, and diagnosis

  2015cites this paper
• Atorvastatin prevents amyloid-β peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway

  2014cites this paper
• Methods for Studying and Structure–Function Relationships of Non-Fibrillar Protein Assemblies in Alzheimer's Disease and Related Disorders

  2014cites this paper
• Towards Non-Invasive Diagnostic Imaging of Early-Stage Alzheimer’s Disease

  2014cites this paper
• Role of Nanocomposites and Nanostructured Biomaterials in Biomedical and Nanobiotechnology.

  2013cites this paper
• Tranilast binds to aβ monomers and promotes aβ fibrillation.

  2013cites this paper
• Caractérisation des oligomères β-amyloïdes cérébraux et vasculaires impliqués dans la maladie d’Alzheimer

  2013cites this paper
• Biomaterials in Biomedical and Nanobiotechnology

  2012cites this paper
• Soluble Aβ oligomer production and toxicity

  2012cites this paper
• Biological Targeting and Activity of Pre-fibrillar Aβ Assemblies

  2012cites this paper
• The Role of Aβ and Tau Oligomers in the Pathogenesis of Alzheimer’s Disease

  2012cites this paper
• Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies.

  2012cites this paper
• Insight into Amyloid Formation Using Congo Red as the Electrochemical Probe

  2011cites this paper
• CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

  2011cites this paper
• Rational design of β-sheet ligands against Aβ42-induced toxicity.

  2011cites this paper
• Abeta Peptide Toxicity is Reduced After Treatments Decreasing Phosphatidylethanolamine Content in Differentiated Neuroblastoma Cells

  2011cites this paper
• Aggregation state and neurotoxic properties of alzheimer β-amyloid peptide.

  2011cites this paper
• Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease

  2011cites this paper
• Development and validation of a yeast high-throughput screen for inhibitors of Aβ42 oligomerization

  2011cites this paper
• The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

  2011cites this paper
• Aβ Conformation Dependent Antibodies and Alzheimer's Disease

  2010cites this paper
• Animal Models to Study the Biology of Amyloid‐β Protein Misfolding in Alzheimer Disease

  2010cites this paper
• Alzheimer's Disease: Synaptic Dysfunction and Aβ The share you. Your matters

  2009cites this paper
• The pathology of APP transgenic mice: a model of Alzheimer's disease or simply overexpression of APP?

  2009cites this paper
• Targeting generation of antibodies specific to conformational epitopes of amyloid beta-derived neurotoxins.

  2009cites this paper
• A Role for Synaptic Zinc in Activity-Dependent Aβ Oligomer Formation and Accumulation at Excitatory Synapses

  2009cites this paper
• Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits.

  2009cites this paper
• Why Alzheimer’s is a Disease of Memory: Synaptic Targeting by Pathogenic Aβ Oligomers (ADDLs)

  2008cites this paper
• Soluble amyloid beta oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma.

  2008cites this paper
• Why Alzheimer’s is a disease of memory: The attack on synapses by Aß oligomers (ADDLs)

  2008cites this paper
• Structure-function relationships of pre-fibrillar protein assemblies in Alzheimer's disease and related disorders.

  2008influential citation
• Role of metal ions in the abeta oligomerization in Alzheimer's disease and in other neurological disorders.

  2008cites this paper
• N-truncated amyloid-β oligomers induce learning impairment and neuronal apoptosis

  2008cites this paper
• Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells.

  2008cites this paper
• Aβ Oligomers – a decade of discovery

  2007cites this paper
• Drug discovery for Alzheimer’s disease

  2007cites this paper
• Role of the APP non-amyloidogenic signaling pathway and targeting alpha-secretase as an alternative drug target for treatment of Alzheimer's disease.

  2007cites this paper
• Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease.

  2007cites this paper
• Small molecule inhibitors of Abeta assembly

  2007cites this paper
• Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease

  2007cites this paper
• Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization.

  2007cites this paper
• Advances on the Understanding of the Origins of Synaptic Pathology in AD

  2007influential citation
• Monoclonal antibodies that target pathological assemblies of Aβ

  2007influential citation
• Cognitive Impairment in Transgenic Aβ and Tau Models of Alzheimer’s Disease

  2007cites this paper
• Acide docosahexaénoïque et maladie d'Alzheimer : des raisons d'espérer ?

  2007cites this paper
• Molecules that Disrupt Memory Circuits in Alzheimer’s Disease: The Attack on Synapses by Aβ Oligomers (ADDLs)

  2007influential citation
• Étude des mécanismes moléculaires impliqués dans la mort neuronale induite par le peptide de ß-amyloïde soluble : recherche et validation fonctionnelle de cibles cellulaires

  2006cites this paper
• Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease

  2006cites this paper
• Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1

  2006cites this paper
• Soluble oligomers of amyloid-β peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway

  2006cites this paper
• The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease.

  2006cites this paper
• ERK1/2 Activation Mediates Aβ Oligomer-induced Neurotoxicity via Caspase-3 Activation and Tau Cleavage in Rat Organotypic Hippocampal Slice Cultures*

  2006cites this paper
• PGH2‐derived levuglandin adducts increase the neurotoxicity of amyloid β1–42

  2006cites this paper
• Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers

  2006cites this paper
• Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology.

  2006cites this paper
• Synaptic targeting by Aβ oligomers (ADDLS) as a basis for memory loss in early Alzheimer's disease

  2006cites this paper
• A specific amyloid-β protein assembly in the brain impairs memory

  2006cites this paper
• Cytotoxic Intermediates in the Fibrillation Pathway: Aβ Oligomers in Alzheimer’s Disease as a Case Study

  2006cites this paper
• Reducing Cerebral Microvascular Amyloid-β Protein Deposition Diminishes Regional Neuroinflammation in Vasculotropic Mutant Amyloid Precursor Protein Transgenic Mice

  2005influential citation
• Nanoscience enables ultrasensitive detection of Alzheimer's biomarker.

  2005cites this paper
• Imaging amyloid beta peptide oligomeric particles in solution.

  2005cites this paper
• Optically and Chemically Encoded Nanoparticle Materials for DNA and Protein Detection

  2005cites this paper
• Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease.

  2005cites this paper
• Imaging amyloid β peptide oligomeric particles in solution

  2005cites this paper
• Two-site binding of beta-cyclodextrin to the Alzheimer Abeta(1-40) peptide measured with combined PFG-NMR diffusion and induced chemical shifts.

  2004cites this paper
• Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

  2004cites this paper
• Per-6-substituted-per-6-deoxy beta-cyclodextrins inhibit the formation of beta-amyloid peptide derived soluble oligomers.

  2004cites this paper
• Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Aβ oligomerization

  2004cites this paper
• Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration.

  2004cites this paper
• Self-assembly of Abeta(1-42) into globular neurotoxins.

  2003cites this paper
• Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss

  2003cites this paper
• Development and validation of a yeast high-throughput screen for inhibitors of A b 42 oligomerization

  year unknowncites this paper